Metagenomi Past Earnings Performance
Past criteria checks 0/6
Metagenomi's earnings have been declining at an average annual rate of -35.9%, while the Biotechs industry saw earnings growing at 19.1% annually. Revenues have been growing at an average rate of 63.2% per year.
Key information
-35.9%
Earnings growth rate
5.3%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 63.2% |
| Return on equity | -28.9% |
| Net Margin | -134.3% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Metagenomi makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 55 | -74 | 33 | 0 |
| 30 Jun 24 | 56 | -75 | 33 | 0 |
| 31 Mar 24 | 47 | -77 | 31 | 0 |
| 31 Dec 23 | 45 | -68 | 29 | 0 |
| 30 Sep 23 | 38 | -64 | 27 | 0 |
| 30 Jun 23 | 31 | -54 | 24 | 0 |
| 31 Mar 23 | 23 | -50 | 21 | 0 |
| 31 Dec 22 | 17 | -44 | 19 | 0 |
| 31 Dec 21 | 0 | -21 | 10 | 0 |
Quality Earnings: MGX is currently unprofitable.
Growing Profit Margin: MGX is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if MGX's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare MGX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MGX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: MGX has a negative Return on Equity (-28.91%), as it is currently unprofitable.